A widely used malaria test is under fire, with a new study claiming it's failing to accurately detect the disease, potentially putting millions at risk.
This isn't just a minor issue; we're talking about a diagnostic tool, the Abbott-Bioline rapid diagnostic test, that's supposed to be a frontline defense against malaria, especially in remote areas. But a recent international study published in the Malaria Journal paints a concerning picture: the test is allegedly delivering too many false negatives, essentially telling people they don't have malaria when they actually do.
The study, conducted by researchers from the Shoklo Malaria Research Unit (SMRU) affiliated with Oxford University, found the test to be alarmingly ineffective, correctly identifying only 18% of Plasmodium falciparum and 44% of Plasmodium vivax infections. That's significantly lower than other rapid tests on the market. The test is widely used in Southeast Asia, where approximately 4 million people are affected by malaria each year, according to the World Health Organization (WHO).
But here's where it gets controversial... Many positive results showed only faint lines, making them difficult to read, especially in less-than-ideal conditions. Imagine trying to read a test in a dimly lit forest during monsoon season – that's the reality for many.
Professor Nicholas White, a co-author of the study, emphasized the gravity of the situation: "Saying, 'You don't have malaria' to someone with falciparum malaria in a very remote area could be a death sentence."
Rapid diagnostic tests are crucial for malaria control, providing quick and accessible treatment in areas without laboratory facilities. However, the Abbott-Bioline test's accuracy is now seriously questioned.
The manufacturer, Abbott Diagnostics, part of Abbott Laboratories, maintains the test is performing as intended. A spokesperson stated that their internal reviews and tests conducted by a WHO-qualified lab confirmed this. They also mentioned they are working on increasing the intensity of the test line to make results clearer. However, this claim is disputed by some experts.
Sunday Atobatele of the Sydani Group, pointed out that faint lines increase the risk of misinterpretation. His study, which covered Nigeria, Uganda, and Benin, revealed that the Abbott-Bioline test showed higher rates of result changes over time compared to other brands. This highlights the importance of proper training, supervision, and validation to ensure reliable results.
And this is the part most people miss... The WHO's response has been criticized as slow. While the WHO has issued a public notice and a technical note, the organization is still working with Abbott to address the concerns, including a site inspection.
François Nosten, another study author, noted that the problem seems to be most prevalent in Southeast Asia, even though the test is sold globally. The Abbott website states that the test is useful in regions where all types of malaria are circulated as it distinguishes P. falciparum infection from others.
The WHO is currently reviewing additional evidence and will assess it against prequalification requirements.
What do you think? Do you believe the manufacturer's claims, or are you concerned about the potential impact of inaccurate test results? Share your thoughts in the comments below!
